Clinical Trial

Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The proposed Conventional Cohort Expansion Study involves the use of Mesenchymal Stromal Cells (MSCs) are derived from the bone marrow. We previously studied the safety of subconjunctival injection of allogeneic bone marrow-derived MSCs in patients with nonhealing epitheliopathy (IRB Protocol 2020-0334). In the present study, we want to study the efficacy of this treatment on chronic epitheliopathies.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-01-21; most recent amendment 2025-12-13.
Status change: Not Yet Recruiting → Recruiting 2023-11-30
Trial Details
NCT Number NCT05705024
Lead Sponsor University of Illinois at Chicago
Collaborators: United States Department of Defense
Conditions Corneal Ulcer
Enrollment 38 participants
Start Date 2023-09-29
Primary Completion 2026-09-28 (estimated)
Study Completion 2026-09-28 (estimated)
Updated on ClinicalTrials.gov 2025-12-16